Michael Becker to Antibodies, Antinuclear
This is a "connection" page, showing publications Michael Becker has written about Antibodies, Antinuclear.
Connection Strength
0.055
-
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 Jul; 76(7):1207-1218.
Score: 0.035
-
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
Score: 0.020